Chattem responds to CARU
This article was originally published in The Rose Sheet
Executive Summary
Chattem agrees to pull TV spot for pHisoderm Clear Confidence Clear Swabfrom children's programming in response to ad review by the Children's Advertising Review Unit, the Council of Better Business Bureaus division says. Chattem did not intend for commercial to air during TV shows directed to young children, and will try to ensure future commercials of this nature do not run during children's programs, CARU states. In a recent inquiry, CARU pointed out its guidelines recommend against advertising medication to children (1"The Rose Sheet" May 19, 2003, p. 5)...
You may also be interested in...
J&J’s Neutrogena, Chattem’s Phisoderm Ads Reviewed By CBBB
Johnson & Johnson agreed to permanently discontinue a TV ad for Neutrogena Deep Clean Gentle Scrub comparing the product's exfoliating properties to competitor formulas following a review by the National Advertising Division of the Council of Better Business Bureaus, according to NAD
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.